This application requests the continued support of the Temple University member institution and six CGOP affiliates. Temple represents a relatively small facility, 505 beds, yet it has modern programs and full clinical resource capabilities. The application admits that this is a relatively new oncologic team. However, most of the ingredients essential for success are in place and SWOG leadership is well represented within this group. The Temple group continues to make leadership and research contributions to SWOG. Dr. MacDonald is chair of the Gastrointestinal Committee, Vice-Chair of the Gastrointestinal Tumor Biology Subcommittee, and study coordinator for INT-0116. Other members, Dr. Silvana Martino, Dr. Patrick Thomas, and Dr. Kenneth Mangan, are involved with central SWOG activities as committee chair and study coordinators, respectively. Research contributions of Temple include pilot molecular biologic correlate studies, and thymidylate synthase regulation and apoptosis studies integrated into SWOG GI cancer protocols. The organization of the Philadelphia Bone Marrow Transplant Consortium, by Dr. Kenneth Mangan, led to a Philadelphia BMT protocol which tested high dose chemotherapy with stem cell support for breast cancer and lead to an intergroup SWOG trial. In addition to leadership and research, a strength of this member institution is its minority recruitment. Temple serves a large population of African-American (45 percent) and Hispanics (15 percent). Twenty-six percent of patients accrued are African-American.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA058415-07
Application #
2879353
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
1993-02-10
Project End
1999-06-30
Budget Start
1999-06-29
Budget End
1999-06-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Temple University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Sosman, Jeffrey A; Moon, James; Tuthill, Ralph J et al. (2011) A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 117:4740-06
Scosyrev, Emil; Ely, Benjamin W; Messing, Edward M et al. (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693-9
Chu, David Z J; Hussey, Michael A; Alberts, David S et al. (2011) Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer 10:310-6
Harigopal, Malini; Barlow, William E; Tedeschi, Greg et al. (2010) Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 176:1639-47
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Sonpavde, Guru; Goldman, Bryan H; Speights, V O et al. (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104-9
Tubbs, Raymond; Barlow, William E; Budd, G Thomas et al. (2009) Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27:3881-6

Showing the most recent 10 out of 54 publications